Status | Study |
Completed |
Study Name: Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Condition: Polycythemia Vera Date: 2012-06-29 Interventions: Drug: Ruxolitinib Ruxolitinib |
Active, not recruiting |
Study Name: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Condition: Polycythemia Vera Date: 2010-11-17 Interventions: Drug: ruxolitinib tablets Star |
Active, not recruiting |
Study Name: Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Condition: Polycythemia Vera Date: 2010-09-01 Interventions: Drug: PEG-P-INF alpha-2b (P1101) µg (starting with 50 µg), subcutaneously, 2-weekly administra |
Completed |
Study Name: Treatment of Polycythemia Vera With Gleevec Condition: Polycythemia Vera Date: 2010-05-07 Interventions: Drug: Gleevec 400 mg once daily for 12 months Other |
Terminated |
Study Name: Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera Condition: Polycythemia Vera Date: 2009-12-22 Interventions: Drug: Erlotinib Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued fo |
Active, not recruiting |
Study Name: Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) Condition: Polycythemia Vera Date: 2009-08-03 Interventions: Biological: blood sample blood sample coming from therapeutic bleeding in hospital |
Withdrawn |
Study Name: Clopidogrel and Aspirin for the Treatment of Polycythemia Vera Condition: Polycythemia Vera Date: 2009-07-14 Interventions: Drug: Clopidogrel (Plavix) Clo |
Completed |
Study Name: Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Condition: Polycythemia Vera Date: 2009-06-25 Interventions: Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea |
Active, not recruiting |
Study Name: A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Condition: Polycythemia Vera Essential Thrombocythemia Date: 2009-03-17 Interventions: Drug: HDAC inhibitor (MK-0683) 400 mg once daily for 6 months |
Recruiting |
Study Name: Molecular Biology of Polycythemia and Thrombocytosis Condition: Polycythemia Thrombocytosis Date: 2008-07-23 |